Akston Biosciences Corporation
100 Cummings Center, Suite 454C
5 articles with Akston Biosciences Corporation
Akston Biosciences Doses First Subjects in Phase II Clinical Trial in India of Second-Generation COVID-19 Vaccine
Akston Biosciences Corporation, a developer of new classes of biologic therapeutics, announced that the first of 100 subjects were dosed in an open-label bridging study of AKS-452, its protein subunit COVID-19 vaccine candidate, in India.
Akston Biosciences Announces Commercial Supply Agreement of Seppic’s Adjuvant to Formulate Akston Shelf-Stable COVID-19 Vaccine at Global Scale
Akston Biosciences Corporation today announced a commercial agreement with Seppic S.A., a supplier of specialty healthcare ingredients, for the supply of adjuvant for use in Akston’s COVID-19 Fc fusion protein vaccine candidate, AKS-452.
Today, Akston Biosciences Corporation , a developer of new classes of biologic therapeutics announced positive results from a 60-subject, open-label, Phase I trial of AKS-452, its protein subunit, room temperature stable, COVID-19 vaccine candidate.
First subjects dosed with AKS-452, COVID-19 vaccine candidate in the Netherlands trial Vaccine is shelf-stable for 4 months at 25 degrees Celsius (77° Fahrenheit) 176 volunteers will participate in the clinical trial
Helmsley Charitable Trust And Akston Biosciences Announce Partnership To Advance Novel Technology To Treat Type 1 Diabetes